Loading the session
Loading the session
Loading instrument
$125.41
−12.70%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:27 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +4.6% (SPY −1.6%, XLV +13.5%). 3 months: +97.6% (SPY −0.6%, XLV +17.0%). 1 year: +78.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GRAL, SPY and XLV · as of 4 Nov 2026
8.2M shares were sold short at the 15 Oct 2026 settlement, 18.3% of the 44.7M shares outstanding; covering them would take 8.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $143.66 was 24.9% above its 50-day average ($115.03) and 82.7% above its 200-day average ($78.63). It has closed above the 200-day for 54 sessions, since 19 Aug 2026. The 50-day average crossed above the 200-day on 10 Sep 2026, 38 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $143.66 on 4 Nov 2026: 13.7% below the 52-week high of $166.48 (6 Oct 2026) and 246.2% above the low of $41.50 (23 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
September 21, 2026
+33.68%February 20, 2026
−50.55%February 13, 2025
+33.93%